Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19166886 | 0.75 | — | — | |
| SCHEMBL5613243 | 0.73 | — | — | |
| SCHEMBL239276 | 0.71 | CA9 (0.36) | — | |
| SCHEMBL15462727 | 0.70 | TSHR (0.37) | GAA | |
| SCHEMBL14071572 | 0.68 | CA9 (0.35) | — | |
| SCHEMBL19165608 | 0.65 | — | — | |
| SCHEMBL16466661 | 0.65 | HSD17B10 (0.32) | — | |
| SCHEMBL28673627 | 0.63 | TRPA1 (0.31) | — | |
| SCHEMBL14071570 | 0.63 | POLB (0.38) | GAA | |
| SCHEMBL23181448 | 0.62 | TUBB1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10374258-B2 | Cyclobutenedione derivative, nonaqueous electrolytic solution, and lithium ion secondary battery | NEC CORPORATION (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10374258-B2 | Cyclobutenedione derivative, nonaqueous electrolytic solution, and lithium ion secondary battery | HSD17B11, HSD17B7, HSD17B2 | MGAM 3664/4885GAA 4257/4885SI 4498/4885 |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | HSD17B11, HSD17B7, HSD17B2 | MGAM 3664/4885GAA 4257/4885SI 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.